The Vasculitis Clinical Research Consortium (VCRC) was established in 2003 and in 5 years of rapid growth and productivity has become the major clinical research infrastructure in North America dedicated to the study of vasculitis. The VCRC is a founding member and leading force of the NIH Rare Diseases Clinical Research Network (RDCRN). By conducting a series of longitudinal cohort studies, biomarker discovery projects, multicenter clinical trials, and outcome measure development projects, the Consortium is addressing serious unmet medical and scientific needs for this group of complex rare diseases. The VCRC currently has over 500 patients in clinical research on the following 6 types of vasculitis: giant cell arteritis, Takayasu's arteritis, polyarteritis nodosa, Wegener's granulomatosis, microscopic polyangiitis, and Churg Straus Syndrome. Each of these diseases are consider """"""""orphan"""""""" diseases. Additionally, partnership with patient advocacy groups has been a critical component to the success of the VCRC. The VCRC electronic resources are important for patients worldwide. The VCRC Fellowship Program has successfully trained new clinical investigators, each of whom remains engaged in academic research in vasculitis. This proposal outlines a total of 13 separate clinical protocols with 10 associated studies of biomarkers VCRC investigators have successfully obtained ancillary funding to allow for expansion of the Consortium's work. Sources of these funds include the NIH, the FDA, private foundation and the biopharmaceutical industry. This application seeks refunding of the VCRC to both support the critical administrative, laboratory, biostatistical cores and allow completion of ongoing projects, launch of exciting new scientific initiatives training of new investigators in clinical research in vasculitis, and expansio n of the VCRC website.
The Vasculitis Clinical Research Consortium (VCRC) combines the clinical and scientific expertise of several major academic medical centers in North America to conduct a series of research projects in several types of vasculitis. Vasculitis is a serious but rare set of diseases and the combined efforts of the VCRC investigators will seek to address important unanswered questions about the causes and best treatments for vasculitis. The VCRC will also teach other physicians about vasculitis and will work closely with vasculitis patient advocacy groups.
|Merkel, Peter A; Xie, Gang; Monach, Paul A et al. (2017) Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. Arthritis Rheumatol 69:1054-1066|
|Langford, Carol A; Cuthbertson, David; Ytterberg, Steven R et al. (2017) A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. Arthritis Rheumatol 69:846-853|
|Milman, N; Boonen, A; Tugwell, P et al. (2017) Clinicians' perspective on key domains in ANCA-associated vasculitis: a Delphi exercise. Scand J Rheumatol 46:112-117|
|Langford, Carol A; Cuthbertson, David; Ytterberg, Steven R et al. (2017) A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. Arthritis Rheumatol 69:837-845|
|Carmona, F David; Coit, Patrick; Saruhan-Direskeneli, Güher et al. (2017) Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy. Sci Rep 7:43953|
|Selewski, David T; Thompson, Aliza; Kovacs, Sarrit et al. (2017) Patient-Reported Outcomes in Glomerular Disease. Clin J Am Soc Nephrol 12:140-148|
|Oommen, Esha; Hummel, Amber; Allmannsberger, Lisa et al. (2017) IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Clin Exp Rheumatol 35 Suppl 103:98-101|
|Gopaluni, Seerapani; Smith, Rona M; Lewin, Michelle et al. (2017) Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. Trials 18:112|
|Carmona, F David; Vaglio, Augusto; Mackie, Sarah L et al. (2017) A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. Am J Hum Genet 100:64-74|
|Sreih, Antoine G; Alibaz-Oner, Fatma; Kermani, Tanaz A et al. (2017) Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016. J Rheumatol 44:1933-1937|
Showing the most recent 10 out of 72 publications